Regulatory
Key facts
FDA approved Lisraya (brepocitinib) tablets for treatment of dermatomyositis in adults
Key facts
Lisraya is a once-daily oral tablet
Key facts
Dermatomyositis is a rare autoimmune disease affecting muscles and skin
Atlas Watchline
The FDA approved Lisraya, a once-daily oral brepocitinib tablet, for adults with dermatomyositis after a phase…